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Cervical cancer (CC) is largely preventable, however, while some high-income countries are nearing elimination status, it remains the leading cause of cancer-related death among women in many low- and middle-income countries (LMIC) [1]. Simms et al showed that with widespread coverage of 
both HPV vaccination and effective cervical screening by 2020, between 12.5 to 13.4 million cases of CC 
could be averted by 2070 [2]. This would, in turn, reduce CC incidence to less than four cases per 100 000, 
and effectively “eliminate” this disease by the end of the century, irrespective of development indices. To-
day, 85% of women diagnosed with cervical cancer live in LMIC [3] and the striking differences in access 
to vaccines, screening tests, diagnostic equipment and treatment between high- and low-income countries 
cannot be ignored. Though not the sole requirement for effective implementation of cancer prevention pro-
grams, without these, urgent scale-up required to achieve elimination in some countries will not be feasible.
LEARNING FROM PAST HEALTHCARE REFORM
We believe that the success of past coordinated efforts to improve access to antiretroviral therapy (ART) 
provides a model we can draw upon to address the present inequities in diagnosing and treating CC. In 
the early 2000s, 95% of people with HIV/AIDS lived in developing 
countries [4]. An estimated 6 million people were in immediate need 
of ART yet only around 300 000 were receiving it [4,5]. At this time, 
a strong climate of global public health reform arose in response to 
the inequities in access to health care between low- and high-income 
countries. At the 4th Ministerial Conference of the World Trade Or-
ganization (WTO) in Doha in November 2001, 142 countries adopt-
ed a historic condition on the TRIPS Agreement and Public Health. 
The “Doha declaration” recognized that while innovation and devel-
opment is critical for medical advancement and requires protection, 
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access of medicines among vulnerable pop-
ulations should be paramount. The Doha 
declaration allowed the production of ge-
neric versions of patented antiretroviral 
(ARV) medicines increasing affordability in 
low-resource settings. It is considered a 
landmark in global health care policy that 
placed public health needs above commer-
cial interests in international trade negotia-
tions. The increase in access to ART that fol-
lowed enabled the transition of HIV/AIDS in 
sub-Saharan Africa from a terminal illness 
to a chronic one. While the Doha declara-
tion has not been a panacea for the inequi-
ties in health care access between low- and 
high-income countries, its impact on the 
HIV/AIDS epidemic provides a compelling case study for today’s global health issues and the discrepan-
cies that exist. Similar efforts are now required to curb the unnecessary mortality arising from CC.
GLOBAL INTERVENTIONS AS THE FOUNDATION FOR REFORM
The WHO initiative to eliminate cervical cancer is an excellent starting point demonstrating consensus 
at a global level to address this public health problem [6]. So far, three interim targets are identified as 
necessary for simultaneous implementation: 90% of girls should be fully vaccinated with the HPV vac-
cine by the age of 15; 70% of women should be screened using a high-performance test by 35 and 45 
years of age; and 90% of women identified with neoplastic disease should be treated. Countries that have 
implemented HPV vaccination programmes alongside high quality screening and diagnostics for CC have 
seen a dramatic decline in CC incidence [7]. In contrast, similar testing and treatment is rarely emulated 
in LMIC. Economic constraints, including the cost of vaccines and diagnostic equipment in laboratories 
and clinics, resulting in reduced access to treatment are barriers to effective cervical screening for vulner-
able women in these settings. Often cervical cancer screening strategies must be negotiated in a delicate 
health care infrastructure, with a scarcity of specialized health care workers, and competing health pri-
orities, and these issues also contribute to this continuing inequality [8,9]. Unless disparities in access to 
vaccines, diagnostics and treatments are addressed, the necessary scale-up required in some countries 
may be impracticable ,[10]. This is recognized in the draft global strategy which specifies the requirement 
for equitable access in the context of universal health care and effective approaches towards resource mo-
bilization.
To reduce the global burden of CC, access to vaccines, diagnostics 
and treatment modalities must be improved. These measures, would 
in turn, assist in strengthening the shrinking health care force in 
LMICs which is, and will be under considerable strain in the pan-
demic era. First, the supply of HPV vaccines must be accelerated, and 
they must be affordable in non-GAVI countries. The current shortage 
in supply means that many countries have to postpone implementa-
tion programs [11]. Furthermore, achieving a price of less than $5 
(not including operational costs) per fully vaccinated girl to ensure 
affordability in LMIC, requires a multi-sectoral approach [12]. Second, efforts to replace visual inspection 
with acetic acid (VIA) with more accurate screening methods are urgently required and the affordability 
of HPV point-of-care testing warrants further evaluation. Third, acceptable treatment must be linked with 
care. Though treatment for pre-cancerous lesions are largely available, African countries remain well be-
low the WHO’s recommendations for radiotherapy services [13] and the availability of analgesic medi-
cines are also limited, with only 11 out of 47 African countries using morphine for pain relief [14]. This 
presents a significant problem as pain is the most common presenting symptom of women presenting 
with cervical neoplasia [15].
One mechanism to reduce prices for essential health products is through licensing agreements between 
patent holders and local generic producers. Compulsory licensing is a mechanism under the TRIPS agree-
Past coordinated efforts to improve ac-
cess to antiretroviral therapy provides 
a model we can draw upon to address 
the present inequities in diagnosing 
and treating cervical cancer and pre-
cancer.
Photo: Internationally, progress towards cervical cancer elimination is unequal. This image was 
developed by the authors for this manuscript.
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ment that allows a government body to grant a license to an entity other than a patent holder, allowing 
them to produce the patented product in exchange for adequate remuneration [16]. We encourage civil 
society, private entities, and LMIC governments to form a strong coalition to push for the use of compul-
sory licensing to improve the availability of low-cost generic HPV vaccines, diagnostics, and treatments 
without risk of trade retaliation [11].
At the global level, there is evidence that the inequities in access to health care in the non-communicable 
diseases (NCDs) era, and specifically relating to CC, are being acknowledged [17]. The WHO has initi-
ated a campaign to increase awareness and initiate action from member states to prioritize vaccination 
and screening programs. Interim targets for synchronized primary and secondary prevention strategies 
have been established. The relationship between these objectives and trade agreements, TRIPS Agreement 
(including the Doha amendment), has been acknowledged in Article 36 of the recent Political Declara-
tion for the high-level meeting on NCDs adopted in October 2018 [18]. Notably, Article 38 explicitly 
states that access to affordable diagnostic, screening, treatment and care, as well as vaccines are integral 
to a comprehensive approach to prevention and control of all NCDs [18]. Operationalizing these senti-
ments requires international co-operation, transparency and accountability. We call for countries to ad-
dress extending the Doha declaration to cervical cancer screening at the TRIPs council within the World 
Trade Organization. At a national level, we urge countries to strengthen their national legal framework to 
facilitate vaccination, screening and treatment and engage with the private sector to safeguard compliance 
with article 36. Cooperation between Member states and the private sector is essential to promote the re-
cent UNGA Political declaration on the prevention and control of NCDs adopted in October 2018. Fur-
thermore, to ensure equitable access to health care services for all, LMIC governments need to develop 
national health care financing policies that include adequate legislative, technical and regulatory frame-
works. We recommend that financing of cancer control be adequately allocated from national health care 
budgets supplemented by innovative financing mechanisms, particularly in countries where rising in-
comes are enabling expansion of public financing for health.
CHALLENGES AND OPPORTUNITIES BROUGHT BY THE COVID-19 
PANDEMIC
In the aftermath of the COVID-19 pandemic, there will be challenges and opportunities for eliminating 
CC. A potentially large proportion of health resources and funding in LMIC will again be siphoned away 
from women’s health and cervical screening, yet CC will remain a pressing health concern. Other chal-
lenges include: (i) unwillingness to access the health facilities for vaccination or routine CC screening due 
to fear of COVID-19 exposure; (ii) inability to access health facilities due to transportation disruptions or 
overall restriction of movement due to lockdown; (iii) disruption to CC screening campaigns in commu-
nities due to risk of exposure during group meetings; (iv) disruption of school-based vaccinations due to 
their closure; (v) health care providers may treat patients differently if they feel unsafe due to lack of ap-
propriate protective equipment, perpetuating further unwillingness of patients to seek medical care; (vi) 
inability to access the screening facility due to facility restrictions and a focus on essential health care pro-
vision only. However, on the positive side is an increasing capacity for and prioritization of treatments 
for patients diagnosed with precancerous and cancerous lesions. Increasing access to protective gear, vac-
cines, diagnostics and treatments would assist in strengthening the shrinking health care force in LMICs 
under considerable strain during the COVID-19 pandemic.
CONCLUSION
A multisectoral approach is required in order to address the global challenges of CC prevention, especial-
ly in the aftermath of the Covid-19 pandemic where health resources will be strained further. The WHO 
initiative to eliminate cervical cancer is an excellent starting point to achieve these goals at the global lev-
el. Economic incentives are also critical to back up these good intentions, and there are lessons we can 
learn from the reform of ART access in the HIV/AIDS context to be applied in an era of non-communi-
cable disease. The health care sector must work with policy makers and industry to promote equitable 
access to resources including life-saving vaccines, diagnostic equipment, and treatments and protective 
equipment. Global health priorities need to address the increasing burden of cervical cancer, which dis-
proportionately affect LMIC, and issues of financing and access must be addressed.
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